Geode Capital Management
JANX icon

Geode Capital Management’s Janux Therapeutics JANX Stock Holding History

Geode Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.5M Buy
1,204,150
+57,426
+5% +$832K ﹤0.01% 2201
2026
Q1 		$15.9M Buy
1,146,724
+33,142
+3% +$454K ﹤0.01% 2123
2025
Q4 		$15.4M Buy
1,113,582
+29,718
+3% +$699K ﹤0.01% 2150
2025
Q3 		$26.5M Buy
1,083,864
+181,552
+20% +$4.42M ﹤0.01% 1858
2025
Q2 		$20.8M Buy
902,312
+121,403
+16% +$3.2M ﹤0.01% 1934
2025
Q1 		$21.1M Buy
780,909
+65,953
+9% +$2.49M ﹤0.01% 1871
2024
Q4 		$38.3M Buy
714,956
+52,362
+8% +$2.77M ﹤0.01% 1599
2024
Q3 		$30.1M Buy
662,594
+38,490
+6% +$1.67M ﹤0.01% 1747
2024
Q2 		$26.1M Buy
624,104
+156,557
+33% +$7.35M ﹤0.01% 1782
2024
Q1 		$17.6M Buy
467,547
+59,357
+15% +$1.29M ﹤0.01% 2000
2023
Q4 		$4.38M Buy
408,190
+21,386
+6% +$185K ﹤0.01% 2772
2023
Q3 		$3.9M Buy
386,804
+9,579
+3% +$110K ﹤0.01% 2767
2023
Q2 		$4.48M Buy
377,225
+22,640
+6% +$303K ﹤0.01% 2744
2023
Q1 		$4.29M Buy
354,585
+14,788
+4% +$246K ﹤0.01% 2702
2022
Q4 		$4.47M Buy
339,797
+5,276
+2% +$77.2K ﹤0.01% 2722
2022
Q3 		$4.53M Buy
334,521
+50,901
+18% +$680K ﹤0.01% 2733
2022
Q2 		$3.46M Buy
283,620
+8,389
+3% +$99.3K ﹤0.01% 2896
2022
Q1 		$3.95M Buy
275,231
+54,704
+25% +$895K ﹤0.01% 2934
2021
Q4 		$4.35M Buy
220,527
+8,647
+4% +$181K ﹤0.01% 2971
2021
Q3 		$4.58M Buy
211,880
+189,863
+862% +$5.46M ﹤0.01% 2956
2021
Q2 		$549K Buy
+22,017
New +$490K ﹤0.01% 3899

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management's JANX Position: Q2 2026 in Review

Geode Capital Management increased its Janux Therapeutics (JANX) stake by 5% in Q2 2026, buying an estimated $832K and bringing the position to 1,204,150 shares worth $18.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2201.

Geode Capital Management first reported a position in JANX in Q2 2021 and has held it in 21 quarters since. The position peaked at $38.3M in Q4 2024. 180 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Geode Capital Management held 1,204,150 shares of Janux Therapeutics worth $18.5M as of Q2 2026.
  • Geode Capital Management bought 57,426 Janux Therapeutics shares in Q2 2026, an estimated $832K.
  • Janux Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2201 holding.
  • Geode Capital Management first reported a position in Janux Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Geode Capital Management's Janux Therapeutics position peaked at $38.3M in Q4 2024.
  • 180 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.